## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.9% below STRENGTH zone (3.0-6.0%); PEG 1.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($12.69)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bearish (Bullish: 0, Bearish: 2)

**1. Acadia Healthcare stock rating reiterated by Cantor Fitzgerald at $17**
- Source: Investing.com | 20251219T130849 | Somewhat-Bearish | Relevance: 100%
- Cantor Fitzgerald has reiterated its Neutral rating and $17 price target for Acadia Healthcare (NASDAQ:ACHC), noting a 17.8% upside from the current price. This decision follows insights from their fourth-quarter Private Hospital Executive Survey, indicating strengthening healthcare volumes and provider optimism for 2026 despite policy headline risks. Other firms like KeyBanc, BofA Securities, and Leerink Partners have adjusted their ratings and price targets due to revised EBITDA guidance and increased costs for Acadia Healthcare.

**2. Bronstein, Gewirtz & Grossman, LLC Encourages Acadia Healthcare Company, Inc. (ACHC) Stockholders to Inquire about Securities Investigation**
- Source: KGET.com | 20251218T210849 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Acadia Healthcare Company, Inc. (ACHC). The firm is encouraging stockholders who purchased Acadia Healthcare securities before February 28, 2020, and still hold them, to assist with the investigation. The investigation focuses on whether the company and its officers engaged in corporate misconduct.

**3. Precision Trading with Acadia Healthcare Company Inc. (ACHC) Risk Zones**
- Source: Stock Traders Daily | 20251218T175400 | Somewhat-Bearish | Relevance: 100%
- This article provides a detailed analysis of Acadia Healthcare Company Inc. (ACHC) revealing a potential exceptional 140.0:1 risk-reward short setup with a target of 38.1% downside. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis also highlights current sentiment with strong near-term sentiment potentially challenging persistent mid and long-term weakness.

**4. Acadia Healthcare (NASDAQ:ACHC) Trading Down 3.5% Following Analyst Downgrade**
- Source: MarketBeat | 20251218T170948 | Bearish | Relevance: 100%
- Acadia Healthcare (ACHC) shares dropped 3.5% after Mizuho lowered its price target from $22 to $17, maintaining a neutral rating. Several other brokers also trimmed their ratings or targets, including Bank of America, Barclays, and Leerink. Despite downgrades, the MarketBeat consensus remains a "Hold" with an average target of $22.75.

**5. Acadia Healthcare (NASDAQ:ACHC) Given New $17.00 Price Target at Mizuho**
- Source: MarketBeat | 20251218T140949 | Somewhat-Bearish | Relevance: 100%
- Mizuho has lowered its price target for Acadia Healthcare (NASDAQ:ACHC) from $22.00 to $17.00, while maintaining a "neutral" rating, indicating a potential 17% upside. This adjustment reflects a broader trend of downgrades and price target cuts by several research firms, contributing to a mixed analyst sentiment with a consensus "Hold" rating and an average target of $22.75. Despite recent financial performance showing an EPS beat and revenue growth, the stock's performance and analyst outlook have shifted downwards.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 9)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $17 | $22 | -23% |
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (18.7%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 36.0% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Momentum building: MRS_10 improving +1.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (9 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 18.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.3 |
| Current P/E | 6.9 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -0.9% to 0.9% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.1pp (needs >3.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.64x), long-term trend not supportive. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.94% (CS: 70) | Neutral |
| RSI_14 | 36.5 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 0.953x | Below |
| vs SMA50 | 0.777x | Below |
| vs SMA200 | 0.640x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $14.41
- **Stop Loss:** $12.69 (11.9% risk)
- **Target:** $16.13 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 697
- **Position Value:** $10,043.77
- **Portfolio %:** 10.04%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*